Spots Global Cancer Trial Database for Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
Official Title: A Single Arm，Multicenter， Phase II Clinical Study to Evaluate the Efficacy and Safety of GLS-010 Injection in the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma
Study ID: NCT03655483
Conditions
Interventions
Study Description
Brief Summary: Patients with refractory cHL. Patients will be treated with GLS-010
Detailed Description: Open, uncontrolled, multi-center, phase II study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Guizhou Cancer Hospital, Guiyang, Guizhou, China
Hunan Cancer Hospital, Changsha, Hunan, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Peking University Cancer Hospital & Institute, Beijing, , China
Contact Details
Name: Jun Zhu, MD
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Name: Yuqin Song, MD
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
